Physician profile
Mark B Weaver
NPI 1801274600
$8,072.53
in general payments reported to CMS, 2019-2025
23 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $673 · 2022: $1,652 · 2023: $2,618 · 2024: $1,647 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,737 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,737.34 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,597.81 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $934.45 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Leo Pharma INC. | $804.84 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $734.80 | 2021-2025 | |
| Ucb, INC. | $724.68 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $696.37 | 2021-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $547.44 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $360.15 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $330.25 | 2022-2025 | Siliq, Targretin, Duobrii |
| Incyte Corporation | $220.43 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $182.15 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $179.71 | 2023-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $163.13 | 2021-2025 | Sotyktu |
| Dermavant Sciences, INC. | $148.65 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $91.32 | 2023-2024 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.49 | 2023 | Cyltezo, Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $65.61 | 2021-2023 | Valchlor |
| Mylan Institutional INC. | $63.86 | 2023 | Hulio |
| Janssen Scientific Affairs, LLC | $50.24 | 2024 | Tremfya |
| Sanofi US Services INC. | $32.55 | 2024 | |
| Galderma Laboratories, L.P. | $29.33 | 2022-2024 | |
| Journey Medical Corporation | $18.18 | 2025 | |
| Mayne Pharma Commercial LLC | $6.09 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.